Three novel NY-ESO-1 epitopes bound to DRB10803, DQB10401 and DRB1*0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients (Q39674556)

13 September 2017

title

Three novel NY-ESO-1 epitopes bound to DRB1*0803, DQB1*0401 and DRB1*0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients (English)

1 reference

13 September 2017

Yu Mizote

1

1 reference

13 September 2017

Taku Taniguchi

2

1 reference

13 September 2017

Kei Tanaka

3

1 reference

13 September 2017

Midori Isobe

4

1 reference

13 September 2017

Hisashi Wada

5

1 reference

13 September 2017

Takashi Saika

6

1 reference

13 September 2017

Shoichi Kita

7

1 reference

13 September 2017

Yukari Koide

8

1 reference

13 September 2017

Akiko Uenaka

9

1 reference

13 September 2017

Eiichi Nakayama

10

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

13 September 2017

19 July 2010

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20665979

full work available at URL

12 June 2024

http://ousar.lib.okayama-u.ac.jp/files/public/5/50954/20160528101328986347/K0004705.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20665979

https://api.elsevier.com/content/article/PII:S0264410X10007425?httpAccept=text/xml

12 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2010.05.044

https://api.elsevier.com/content/article/PII:S0264410X10007425?httpAccept=text/plain

12 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2010.05.044

12 June 2024

1 reference

13 September 2017

volume

28

1 reference

13 September 2017

issue

32

1 reference

13 September 2017

page(s)

5338-5346

1 reference

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Cancer/testis antigens, gametogenesis and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

NY-ESO-1: review of an immunogenic tumor antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

A survey of the humoral immune response of cancer patients to a panel of human tumor antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Use of MHC class II tetramers to investigate CD4+ T cell responses: problems and solutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Identification of a novel NY-ESO-1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.044

Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade

7 January 2021

20

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2010.05.044

NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells

12 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2010.05.044

NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells

12 June 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2010.05.044

12 June 2024

Identifiers

1 reference

13 September 2017

1 reference